Background--Critical limb ischemia (CLI) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence.
P eripheral artery disease (PAD) affects 3% to 10% of all Americans and 15% to 20% of persons 70 years of age and older. PAD is particularly common among individuals who smoke or have diabetes mellitus.
1,2 A subset of patients with PAD have critical limb ischemia (CLI), which is characterized by varying degrees of foot or ankle pain at rest and/or the presence of ischemic ulcerations or necrotic tissue. The incidence of CLI in the United States is estimated to be between 500 and 1000 per million per year. Given the aging of the American population, the global increase in metabolic syndrome, and the ongoing impact of diabetes mellitus and tobacco use, the prevalence of both PAD and CLI is predicted to further increase. 1 In addition, management of CLI has substantial healthcare and societal costs, 3, 4 and these are expected to grow given current demographic, disease, and economic trends. 1 CLI is associated with significant disability, morbidity, and mortality. In the absence of successful revascularization, 20% to 40% of patients will require amputation and over 20% will die within 6 months. 1, 2, 5 In a recently published large German registry, CLI with tissue loss was associated with 4-year amputation rates of 35% to 67% and mortality rates ranging from 52% to 64%. 6 Because of the absence of medical therapy effective for salvage of threatened legs, CLI is typically treated with revascularization to improve limb perfusion distal to the zone of arterial stenosis or occlusion. Open surgical bypass has historically been the standard of care for patients with infrainguinal PAD and is associated with excellent limb salvage rates and clinical durability. 7 Outcomes of surgical bypass are significantly affected by the quality of the conduit utilized, 8, 9 the severity of ischemia at presentation, 10 and the extent of infrainguinal arterial obstruction. 10 Over the last 2 decades, the widespread adoption of endovascular techniques has led to a sharp increase in their application to patients with CLI 11, 12 and there are numerous reports of excellent limb salvages rates. 13, 14 In comparison to surgical bypass, endovascular therapy is associated with decreased periprocedural morbidity and mortality. However, questions about durability, cost, and appropriate case selection have not been rigorously answered. 15, 16 At present, a variety of practitioners, including interventional cardiologists, vascular medicine specialists, interventional radiologists, and vascular surgeons, provide treatment for CLI. 17 The decision to recommend surgical or endovascular revascularization varies significantly among providers and institutions and appears to be based on such factors as disease pattern, the availability of autogenous conduit, physician training and experience, surgical and endovascular skill sets, access to an appropriate procedural environment, and perhaps most importantly, treatment bias. 15, [18] [19] [20] This lack of treatment uniformity is highlighted by the marked degree to which the primary treatment of CLI varies within the Society of Vascular Surgery (SVS) Vascular Quality Initiative, as illustrated in Figure 1 . 21 There is general agreement that some patients considered poor candidates for surgery benefit from endovascular revascularization. 22, 23 What remains unknown is which therapy is most appropriate for patients who are candidates for both open and endovascular treatment. This uncertainty also has economic implications, potentially leading to suboptimal allocation of valuable healthcare resources. 15 The lack of consensus underlying the current therapeutic approach to CLI directly stems from insufficient high-quality data upon which to base treatment decisions. Although there are many studies evaluating management strategies for CLI, most have limitations arising from their use of retrospective data with incomplete control for potential confounders, sponsor and operator bias, inclusion of claudicants, and short or incomplete follow-up. 24, 25 To date, there is only 1 prospective randomized trial comparing endovascular techniques with surgical revascularization for limb ischemia, the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. 26, 27 Endovascular treatment in BASIL was limited to percutaneous transluminal angioplasty alone, as was standard practice in the United Kingdom where the trial was undertaken; as such, the applicability of the trial result to current practice in North America, which typically includes the use of stents, atherectomy, and drug-coated balloons, has been questioned. 15, 16 The choice of amputation-free survival (AFS) as the primary end point in the BASIL trial has also been criticized, as it overemphasizes non-treatment-related mortality and underemphasizes limb-related events specifically attributable to treatment modality.
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The BEST-CLI (Best Endovascular versus Best Surgical Therapy in patients with Critical Limb Ischemia) trial was conceived to provide level I comparative-effectiveness evidence to help guide treatment decisions in the management of CLI. 28, 29 The trial will furnish contemporary information about therapeutic outcomes in patients with CLI who are candidates for either surgical bypass or endovascular therapy. It will also provide high-quality cost-effectiveness data about surgical and endovascular approaches to treating CLI, and the impact of those treatments on the quality of life (QoL) and overall function of the study population. Patients in the latter cohort who are randomized to surgical revascularization will be treated with surgical bypass using an arm vein, short saphenous vein, cryopreserved vein, prosthetic conduit, or composite conduit. Within each cohort, randomization will be stratified according to (1) clinical presentation, defined by presence of ischemic rest pain alone (Rutherford 4) versus tissue loss (Rutherford 5 and 6) with or without ischemic rest pain and (2) anatomic status, defined by the presence or absence of significant tibial disease. Randomization is accomplished using computer-generated permuted blocks within each of the 8 combinations of cohort and stratum.
The trial is being conducted in accordance with the Declaration of Helsinki ethical standards 30 and with adherence to the rules and regulations of the Institutional Review Board at each participating institution. All subjects are required to provide written informed consent using an Institutional Review Board-approved consent form. Research reported in this publication is supported by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health under Award Numbers U01HL107352, U01HL107407, and U01HL115662 (clinicaltrials.gov NCT02060630). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. An Investigational Device Exemption was granted by the Food and Drug Administration to allow investigator use of Food and Drug Administration-approved devices in an off-label fashion consistent with routine practice and current standards of care.
Inclusion and Exclusion Criteria
Patients appropriate for the BEST-CLI trial must satisfy all of the inclusion and exclusion criteria and be considered suitable candidates for both endovascular and open surgical revascularization by at least 2 investigators at the participating trial site. At least 1 of the 2 investigators must be credentialed to perform endovascular revascularization and the other must be credentialed to perform open surgical bypass. One year after initiation of the trial, several modifications to the inclusion and exclusion criteria were approved by the Data and Safety Monitoring Board (DSMB). The changes incorporated investigator feedback and served either to clarify confusing elements of the criteria or to enhance enrollment while preserving the core objectives and aims of the trial. Table 1 compares the original and modified inclusion and exclusion criteria. Enrolled patients must have adequate aortoiliac inflow, as defined in Table 2 , and appropriate proximal and distal anastomotic targets for a surgical bypass. The definition of CLI 10 is listed in Table 3 .
Randomization
The patient flow diagram for the BEST-CLI trial is depicted in Figure 2 . Subjects meeting all of the inclusion and none of the exclusion criteria are randomized within the outlined schema based on the results of a contrast angiogram of sufficient quality performed within the preceding 3 months. Any prior index limb infrainguinal stenting or stent grafting associated with significant restenosis within 1 cm of the stent or stent-graft, unless the occlusion/restenosis site is outside the intended treatment zone (ie, a tibial vessel that is not currently intended to be revascularized as a part of the treatment for CLI)
Any of the following procedures performed on the index limb within 6 months prior to enrollment: combination of the above should they be randomized to surgical bypass. Subjects enrolled in Cohort 1 who are subsequently found to have saphenous vein that is insufficient in length or quality to perform a single-segment bypass and who instead undergo bypass with an alternative conduit will be analyzed on an intention-to-treat basis in their originally designated cohort. Similarly, any subject enrolled into Cohort 2 and subsequently found at the time of bypass surgery to have a sufficient single segment of saphenous vein will remain in Cohort 2 for the intention-to-treat analysis.
Investigators have the option of randomizing and treating a subject immediately following confirmatory diagnostic angiography, or waiting until a later time to randomize. The assigned treatment must be undertaken within 30 days of randomization.
Study Procedures and Follow-Up
For BEST-CLI trial subjects with associated aortoiliac occlusive disease, concomitant treatment of the aortoiliac disease at the time of the index infrainguinal revascularization is allowed for patients with ischemic tissue loss. Patients presenting with ischemic rest pain as their sole manifestation of CLI, in contrast, must first undergo treatment of the aortoiliac segment to correct the suprainguinal inflow. Randomization of such subjects is subsequently allowed if they have persistent rest pain symptoms and continue to meet the hemodynamic definition of CLI on repeat assessment.
Since the BEST-CLI trial aims to compare endovascular versus open approaches, hybrid procedures combining elements of both endovascular and open surgical treatment of infrainguinal disease were initially prohibited. Following modifications to the BEST-CLI trial protocol approved by the DSMB in August 2015 (Table 1) , investigators are allowed to combine surgical endarterectomy of the common femoral artery with postrandomization endovascular treatment of more distal disease. For patients with rest pain who undergo either open surgical or endovascular treatment of common femoral disease, a similar requirement to confirm persistence of rest pain symptoms and continued hemodynamic criteria of CLI after treatment of the common femoral artery and prior to randomization into the trial remains in place.
Although discouraged, unplanned staged revascularization following randomization to endovascular treatment is allowed if considered necessary (eg, in the event of patient intolerance of conscious sedation, concern for contrast dye load or radiation exposure) for up to 4 days following the initial endovascular effort, provided that the initial treatment rendered is well documented and the treatment plan for the subsequent stage is clearly delineated. Retreatment of lesions treated in the initial stage will be considered reinterventions or treatment failures.
The outline of postrevascularization follow-up visits and the parameters to be measured is listed in Table 4 .
Primary and Secondary End Points
The primary efficacy end point in the BEST-CLI trial is Major Adverse Limb Event (MALE)-free survival (Table 5 ). This aggregate measure best captures the therapeutic goals of treatment for CLI, which include preservation of a functional limb and avoidance of major reinterventions that significantly impact QoL. Accurately assessing limb-related morbidity and procedure-related need for reintervention is of paramount importance in a trial comparing revascularization strategies, particularly in light of remaining questions regarding treatment durability. The MALE end point was devised by the SVS Objective Performance Goals Working Group specifically for use in clinical trials involving CLI patients. 10 This end point has been endorsed by both the SVS and the Food and Drug Administration. 10, 15, 31 MALE captures all major repeat vascular procedures on the index limb, including above-ankle amputation and major reinterventions, defined by the creation of a new bypass graft, a jump/interposition graft revision, surgical thrombectomy with or without surgical patch angioplasty, and thrombectomy of an occluded graft or arterial segment using pharmacologic or mechanical thrombolysis. Notably, MALE excludes minor reinterventions, defined as surgical patch angioplasty (without graft thrombectomy), percutaneous transluminal angioplasty, atherectomy, laser treatment and/or stenting, or stent/grafting via either an open surgical exposure or percutaneous approaches, which are presumed to have less clinical impact. MALE-free survival is felt to be superior as a primary efficacy end point to the historic standard of AFS, given that the primary goal of limbdirected therapies for CLI is not to prolong survival but rather to relieve ischemic rest pain and heal leg-threatening tissue loss. The failure of AFS to capture major treatment-related reinterventions, and their direct impact on QoL and cost, significantly limits its utility in a trial designed to compare effectiveness of revascularization strategies. Nonetheless, because it combines 2 penultimate events of greatest magnitude for the CLI patient, AFS is included as a key secondary end point. Reintervention and amputation-free survival is an additional important secondary end point that is defined as survival free from above-ankle amputation of the index limb or major or minor reintervention. The BEST-CLI trial will also examine MALE-Peri-Operative Death, which includes 30-day perioperative mortality but excludes longer-term mortality that is less likely related to the treatment of the limb. Table 5 lists the definitions of the major and key secondary end points, as well as those of additional secondary and safety end points. Freedom from clinical failure, freedom from CLI, and freedom from hemodynamic failure are particularly important end points that evaluate the end result of enhanced limb perfusion and the sustained hemodynamic impact of the treatment received in a way that has rarely been done in other PAD trials to date. Functional and QoL secondary end point assessments include the Numerical Rating Scale for pain, 32 Vascular Quality of Life Questionnaire (VascuQoL), 33 EuroQoL five dimensions questionnaire (EQ-5D), 34, 35 and 12-Item Short-Form Health Survey (SF-12). 36 At a subset of sites, the 6-minute walk test will also be performed. 37 Treatmentassociated costs (in-and outpatient) and incremental costeffectiveness measured in dollars per quality-adjusted life year will also be measured. the National Heart, Lung and Blood Institute, and is responsible for the day-to-day conduct of the trial. The Executive Committee (EC) comprises members of the Operations Committee, in addition to leading experts in the disciplines of vascular medicine, interventional radiology, interventional cardiology, and vascular surgery ( Table 6 ). The balance of subspecialty membership of the EC reflects the mix of clinical disciplines currently managing patients with CLI within the United States and Canada. The EC meets in person or by phone on a monthly basis and serves in both an advisory and an oversight role. An independent Protocol Review Committee of individuals with appropriate expertise was appointed by the National Heart, Lung and Blood Institute and was responsible for approval of the initial BEST-CLI trial Protocol. Subsequently, a DSMB was constituted in part from members of the Protocol Review Committee. The DSMB meets semiannually over the course of the trial and has ongoing responsibility for the overall safe conduct of the trial, as well as approval of any protocol amendments and ancillary studies. A multidisciplinary Clinical Events Classification Committee, comprised of board-certified physicians with appropriate specialist training, will review and adjudicate all first major reinterventions on the index limb, as well as all myocardial infarctions and strokes. Identification of suspected events will arise from review of each patient's electronic case report forms and collected source documents. Clinical Events Classification Committee members will be blinded to study treatment assignment, and event adjudication will be undertaken in a manner independent of the BEST-CLI trial EC, Operations Committee, and all participating site investigators. Two boardcertified physician specialists will serve as Independent Medical Reviewers, and review source documents for a random sample of site-reported minor reinterventions, to confirm that they were not misidentified major reinterventions.
Trial Organization and Oversight
Trial sites currently participating in the BEST-CLI trial are listed in Appendix A and the geographic distribution of sites is depicted in Figure 4 .
Subcommittees
There are 7 BEST-CLI Trial subcommittees (the chairs of which are listed in Appendix B). These include the following: with reviewing all trial-related content as it pertains to dissemination of scientific information emanating from the BEST-CLI trial. This committee will prioritize queries of the database and act to ensure the scientific integrity of all trial-related press, presentations, and publications.
Statistical Considerations

BEST-CLI is designed as 2 separate concurrent trials (in Cohort 1 and in Cohort 2). There is no intent to pool the data between
Cohorts, or to test whether the treatment group effects (if any) are similar between the 2 Cohorts. To avoid bias, particularly given that the BEST-CLI trial by its nature cannot be a blinded study, all analyses will be on the basis of intention-to-treat unless otherwise specified. Per intention-to-treat, all participants will be analyzed in the Cohorts in which they were classified at the time of randomization, and all participants will be analyzed in the treatment groups to which they were randomly assigned, even if the other type of revascularization strategy was carried out instead or they did not undergo any revascularization procedure within the 30-day window following randomization. There will also be an exploratory perprotocol analysis, including only subjects who adhered to their randomly assigned treatment strategy. However, this analysis will be subject to bias, as the subjects who do not undergo their assigned procedure are unlikely to be a representative sample of all subjects assigned to that procedure. For each outcome, the null hypothesis is that there is no difference in that outcome between the 2 treatment groups. The alternative hypothesis is that there is a difference, in either direction, between the treatment groups; ie, the statistical tests will be 2-sided. In each cohort, the primary analysis of the primary outcome will be a Cox regression model of time to major revascularization of the index limb, above-ankle amputation of the index limb, or death from any cause, whichever occurs first. Participants who do not experience a primary outcome event will be considered censored on the last date of study contact. The Cox model will be stratified by randomization stratum, which allows the baseline hazard function to differ between the 4 randomization strata, but assumes a common hazard ratio between endovascular versus open revascularization in all 4 strata. The Cox model will also be adjusted for the following prespecified list of baseline covariates, all of which are expected to be strong predictors of the primary outcome: end-stage renal disease, diabetes mellitus, prior revascularization of the index leg, and smoking history.
Other time-to-event outcomes will be analyzed in a similar way, using covariate-adjusted Cox models stratified for randomization stratum. Table 7 shows which covariates will be adjusted for in the models for each time-to-event outcome. Mixed-model linear regression will be used to examine treatment effects for continuous outcomes such as the various QoL measures, both longitudinally and with contrasts of treatment differences at specific time points. A Wilcoxon rank sum test will be used to compare 6-minute walk times from the Month 6 visit. Rates of procedure complications in the first 30 days after the index procedure will be compared using Poisson regression, and Fisher's exact test will be used to compare the proportion of subjects with at least 1 procedure complication. Rates of adverse events will also be compared using Poisson regression.
The primary cost-effectiveness analysis will use measures of costs and outcomes occurring during the trial period to estimate differences in incremental dollars per incremental quality-adjusted life-year. In addition, a Markov state-transition model will be developed to estimate the cost-effectiveness of each treatment strategy over a lifetime horizon. Costs will be estimated by multiplying the magnitude of resources each patient consumes by unit prices obtained from nationally and regionally representative data sources. 38, 39 Subgroup analyses of the primary outcome will be carried out using Cox models, including an interaction term between treatment group and a participant characteristic known at baseline. In each Cohort, the following subgroup analyses have been prespecified: 5 Ethnicity (Hispanic versus non-Hispanic) 6 Race/ethnicity (Hispanic versus black non-Hispanic versus all others) 7 Age <80 years versus ≥80 years 8 Presence versus absence of diabetes mellitus 9 Presence versus absence of Wound, Ischemia, and foot Infection Grade 3 wound on index limb 40 10 Presence versus absence of renal dysfunction 11 Absence of renal dysfunction versus non-dialysis-dependent renal dysfunction versus dialysis-dependent renal dysfunction
The DSMB will monitor the trial to enhance participant safety and the scientific integrity of the study. Interim analyses of the primary outcome and all-cause mortality will be performed, using stopping guidelines based on an aspending approach approximating O'Brien-Fleming boundaries. 41 The DSMB may recommend stopping the trial early in a particular cohort (or in both cohorts), based on the totality of evidence, including results of these analyses, adverse event rates in each treatment group, new information from outside the BEST-CLI trial, and other considerations. Table 8 shows the statistical power available in Cohort 1 to detect various true differences in several of the study outcomes at the 0.05 significance level, assuming the specified true event rates for each treatment group before any crossovers (treatment violations). Additional assumptions include the following: 5% premature cessation of study followup, 2% of participants assigned to endovascular therapy receiving open surgery instead, 10% of participants assigned to open surgery receiving endovascular therapy instead, 24 months of accrual with a slow ramp-up of enrollment rates at the start of the trial, 26 months of additional follow-up after the end of the enrollment period, and 2% sample-size inflation to take into account interim monitoring. Table 9 shows similar information for Cohort 2.
Results and Discussion
The BEST-CLI trial aims to provide Level I evidence that will significantly enhance therapeutic decision-making and help establish a much-needed standard of care for patients with CLI. Recent data from the SVS Vascular Quality Initiative highlight the remarkably high degree of equipoise currently associated with the treatment of CLI in North America (Figure 1) . 21 The widely disparate and often tightly held treatment biases regarding the relative role of open surgical and endovascular therapy for CLI serve as the central rationale and ongoing motivation for a trial such as BEST-CLI. Several unique features of the BEST-CLI trial bear further mention, among them the trial design, comprehensive costeffectiveness and quality of life analyses, use of novel end points, and collaborative approach. The trial focuses on patients with CLI who are candidates for both infrainguinal open surgical and endovascular revascularization and was purposely designed as a pragmatic trial. The most significant feature of such a design is that the definition of what constitutes "best" therapy within the assigned revascularization approach is left to each individual investigator. Accordingly, all commercially available endovascular therapies (with the exception of cryoplasty) are allowed, as are all surgical bypass techniques and types of conduit. This pragmatic element is of particular importance in the effort to avoid the common pitfall of conducting a trial that is of limited relevance to current clinical practice by the time of final analysis. 42 The BEST-CLI trial has a robust cost-effectiveness component that will serve to quantify the accumulated financial costs in each intervention arm. In addition, the trial will analyze a wide spectrum of relevant functional and QoL outcomes. Because endovascular and open revascularization may be associated with either similar or different rates of treatment success, assessing the additional safety, costeffectiveness, and QoL end points will be critical to accurately capturing the entirety of the clinical and economic benefit of each therapy. Cost-effectiveness analysis will be based on longevity, QoL, and the economic value of any observed differences in these outcomes. This analysis will rely on prospectively collected information to characterize the resources consumed during each subject's initial revascularization hospitalization and all related subsequent inpatient and outpatient contacts with the medical system, including repeat hospitalization, outpatient physician visits, outpatient tests and procedures, emergency department visits, and medication use. The main measures of functional outcome will be EQ-5D and VascuQoL, which are standardized, wellvalidated instruments. The VascuQoL, a disease-specific questionnaire that makes it possible to detect subtle changes in disease severity, will be used as the main CLI-specific QoL outcome tool. 33 EQ-5D comprehensively gauges global healthrelated QoL and utilities, and will be the primary measure for cost-utility analysis. 35 Given the limitations of the widely used Rutherford classification system, the SVS has recently developed a novel classification scheme for lower-extremity threatened limbs, known as WIfI (Wound, Ischemia, and foot Infection), that is based on the extent and depth of wounds, the degree of ischemia, and the presence and extent of infection. 40 In addition to capturing the TransAtlantic Inter-Society Consensus anatomic status of the index extremity, the BEST-CLI trial has incorporated and aims to prospectively validate this novel Wound, Ischemia, and foot Infection classification system. The trial also utilizes a number of novel end points intended to capture all outcome parameters of interest. Some of these end points will focus on the implications of reinterventions, both major and minor, while others will directly measure the clinical and hemodynamic consequences of the CLI treatments under investigation.
Recognizing the degree to which CLI is currently managed by a range of subspecialists in the United States and Canada, principally vascular surgeons, interventional cardiologists, interventional radiologists, and vascular medicine specialists, every effort has been made to make the BEST-CLI trial a fully multidisciplinary endeavor. To have the trial most accurately reflect contemporary practice and, to the extent possible, have the results accepted by the entire spectrum of CLI caregivers, it was felt important to have all those providing CLI care at participating BEST-CLI trial sites involved. Towards this end, the creation of "CLI teams" has been promoted at each institution. The goals of the CLI team include supporting the enrollment of patients, creating and fostering an environment conducive to constructive communication and physician collaboration, and ensuring standard-of-care treatment within the strategy to which each subject has been randomized. A hallmark of the CLI team is the requirement that each patient be reviewed by a minimum of 2 members of the CLI team: 1 credentialed in endovascular treatment and the other credentialed for open surgical revascularization. This same requirement also applies to any randomized subject being considered for reintervention.
Further underscoring the collaborative design and intent of the BEST-CLI trial, the EC, the Clinical Events Classification Committee, the DSMB, and each of the 7 subcommittees detailed above has well-balanced representation from all participating disciplines. Finally, and as an additional reflection of the efforts to integrate the contributions of all interested parties, the BEST-CLI trial has received a broad level of support from numerous relevant professional societies and organizations. The trial has been formally endorsed by the SVS, the Society of Interventional Radiology, the Society for Cardiovascular Angiography and Intervention, the Society of Vascular Medicine, the Vascular Disease Foundation, Vascular InterVentional Advances, and the Food and Drug Administration.
Limitations
The pragmatic design of the BEST-CLI trial accommodates the spectrum of revascularization techniques in current use by participating specialists. In so doing, it optimizes investigator engagement and subject enrollment and maximizes the generalizability and long-term relevance of the trial. Inclusion of such a broad array of open and endovascular therapies, however, introduces significant heterogeneity into the data set and may limit the ability to ascertain the relative effectiveness of specific treatment techniques. The generalizability of the trial could also be compromised if practice patterns during the trial do not mimic those outside of trial conditions. Additionally, although certain strata have been prespecified according to anticipated differences in outcome, additional factors may prove to be equally or more relevant and the statistical power may be insufficient to detect the importance of such parameters.
Conclusions
CLI continues to represent a formidable healthcare challenge. Over and above its major impact on the morbidity, mortality, and QoL of a growing number of patients with PAD, the associated financial burden on our healthcare economy is substantial and growing. The BEST-CLI trial is a timely and much-needed study that will help to define best practice and provide a foundation for thoughtful application of current and future treatment options. More information on the BEST-CLI trial can be found at www.BESTCLI.com and through clinicaltrials.gov: NCT02060630. BEST-CLI Trial Policy for Conditional Approval of Investigators. In an effort to ensure the highest level of quality and safety for patients enrolled in the BEST-CLI trial, the Surgical and Interventional Management Committee (SIMC) has decided to recognize junior investigators who are within 24 months of graduation from their specialty training program, and who otherwise are felt appropriate for participation as BEST-CLI investigators, as "Conditionally Approved" to provide revascularization services as part of the trial. The SIMC strongly encourages Conditionally Approved investigators to enroll any eligible critical limb ischemia patients in their practice into the BEST-CLI trial. Conditionally Approved investigators should perform revascularization procedures with a proctor/collaborator who is a fully approved investigator for revascularization procedures in the BEST-CLI trial. The status of such investigators will be reviewed on a yearly basis to determine if sufficient experience has been gained to warrant a change to full credentialing as an "Approved" investigator.
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